BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 9558917)

  • 1. [Results of treatment of Graves-Basedow disease with 131I at low calculated doses].
    Gómez Arnaiz N; Gómez Saez JM; Orti Llavería A; Gavaldá Mestre L; Mairal Pairó L; Soler Ramón J
    Rev Clin Esp; 1998 Feb; 198(2):57-60. PubMed ID: 9558917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative evaluation of two fixed doses of 185 and 370 MBq 131I, for the treatment of Graves' disease resistant to antithyroid drugs.
    Esfahani AF; Kakhki VR; Fallahi B; Eftekhari M; Beiki D; Saghari M; Takavar A
    Hell J Nucl Med; 2005; 8(3):158-61. PubMed ID: 16390021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
    Metso S; Jaatinen P; Huhtala H; Luukkaala T; Oksala H; Salmi J
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):641-8. PubMed ID: 15521969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A simplified method for treating Graves' disease with radioactive 131I.
    Masri MT; Menne M; Rooney BL; Caplan RH
    Wis Med J; 1995 Jan; 94(1):21-5. PubMed ID: 7871797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transient hypothyroidism after iodine-131 therapy for Grave's disease.
    Gómez N; Gómez JM; Orti A; Gavaldà L; Villabona C; Leyes P; Soler J
    J Nucl Med; 1995 Sep; 36(9):1539-42. PubMed ID: 7658207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term carbimazole intake does not affect success rate of radioactive 131Iodine in treatment of Graves' hyperthyroidism.
    El Refaei SM; Shawkat W
    Nucl Med Commun; 2008 Jul; 29(7):642-8. PubMed ID: 18528187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up study of compensated low-dose 131I therapy for Graves' disease.
    Sridama V; McCormick M; Kaplan EL; Fauchet R; DeGroot LJ
    N Engl J Med; 1984 Aug; 311(7):426-32. PubMed ID: 6205272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What influences early hypothyroidism after radioiodine treatment for Graves' hyperthyroidism?
    Vijayakumar V; Ali S; Nishino T; Nusynowitz M
    Clin Nucl Med; 2006 Nov; 31(11):688-9. PubMed ID: 17053385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.
    Berg GE; Michanek AM; Holmberg EC; Fink M
    J Nucl Med; 1996 Feb; 37(2):228-32. PubMed ID: 8667049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioactive iodine in the treatment of Graves' disease.
    Al-Kaabi JM; Hussein SS; Bukheit CS; Woodhouse NJ; Elshafie OT; Bererhi H
    Saudi Med J; 2002 Sep; 23(9):1049-53. PubMed ID: 12370710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relapse of Graves' disease 23 years after treatment with radioactive iodine (131I).
    Hegele RA; Volpé R
    J Clin Lab Immunol; 1985 Oct; 18(2):103-5. PubMed ID: 3841162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of hyperthyroidism caused by Graves' disease or toxic multinodular goitre by radioiodine: over 80% cure retrospectively after one calculated dose].
    Bakker SC; Zanin DE; Zweers EJ
    Ned Tijdschr Geneeskd; 2002 Sep; 146(39):1837-41. PubMed ID: 12382370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study.
    Howarth D; Epstein M; Lan L; Tan P; Booker J
    Eur J Nucl Med; 2001 Oct; 28(10):1489-95. PubMed ID: 11685491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I.
    Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
    Phys Med Biol; 2005 May; 50(9):2181-91. PubMed ID: 15843745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [131I therapy in hyperthyroidism. Results of treatment from 1960-1974].
    Heinze HG; Schenk F
    Nuklearmedizin; 1977 Feb; 16(1):1-12. PubMed ID: 846862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term results following 131I treatment for Graves' disease in Hong Kong Chinese--discriminant factors predicting hypothyroidism.
    Kung AW; Pun KK; Lam KS; Choi P; Wang C; Yeung RT
    Q J Med; 1990 Sep; 76(281):961-7. PubMed ID: 2236479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of Graves-Basedow's disease with 131I. Assessment of a "modulated fixed activity" protocol].
    Abós D; Ruiz P; Prats E; Razola P; García F; Tardín L; Banzo J
    Rev Esp Med Nucl; 2007; 26(1):3-10. PubMed ID: 17286943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal iodine-131 dose for eliminating hyperthyroidism in Graves' disease.
    Nordyke RA; Gilbert FI
    J Nucl Med; 1991 Mar; 32(3):411-6. PubMed ID: 2005449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the long-term efficacy of low dose 131I versus antithyroid drugs in the treatment of hyperthyroidism.
    Chen DY; Jing J; Schneider PF; Chen TH
    Nucl Med Commun; 2009 Feb; 30(2):160-8. PubMed ID: 19194213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Follow-up and long-term results of radioiodine therapy in immune hyperthyroidism].
    Galvun G
    Acta Med Austriaca; 1987; 14(3-4):99-101. PubMed ID: 3425189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.